Alzheimer's Disease Market Expected to Grow to $5,038 Million by 2025

The Alzheimer's Disease market was valued at an estimated USD 5,038 million in 2025. Projections indicate a significant expansion at a compound annual growth rate (CAGR) of 23.7% throughout the forecast period ending in 2034.

The United States represented the largest share of the market in 2023, accounting for approximately 54% of the total 7MM (United States, EU4, UK, Japan). Within the EU, Germany held the largest market share at USD 267 million, while the UK had the smallest at around USD 104 million. Japan's market was valued at approximately USD 845 million in the same year.

Globally, the 7MM recorded an estimated 16 million diagnosed prevalent cases of Alzheimer's Disease in 2024, with the US accounting for roughly 7 million cases. This prevalence is expected to increase by 2034, indicating a growing healthcare burden.

The disease is categorized by severity, including mild cognitive impairment (MCI), mild, moderate, and severe dementia. In 2024, MCI was the most common stage within the EU4 and UK, affecting approximately 2.6 million individuals. Increased prevalence of agitation associated with Alzheimer's was also noted in Spain.

Anticipated market growth is linked to the introduction of new therapies, such as Masitinib, Valiltramiprosate, and Bezisterim. Key companies in the Alzheimer's Disease landscape include Biogen Inc./Eisai Co., Ltd., Eli Lilly and Company, and Hoffmann-La Roche. The report also notes that Alzheimer's Disease is more prevalent in women than in men.